| Catalog No. |
TD-HW342026 |
| Species reactivity |
Human |
| Applications |
Research Grade Biosimilar |
| Host species |
Humanized |
| Isotype |
IgG1-kappa |
| Expression system |
Mammalian Cells |
| Clonality |
Monoclonal |
| Target |
ACT35 antigen, TXGP1L, TAX transcriptionally-activated glycoprotein 1 receptor, Tumor necrosis factor receptor superfamily member 4, TNFRSF4, OX40L receptor, CD134 |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G, purified from cell culture supernatant. |
| Accession |
P43489 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS,pH7.4. |
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names |
Vonlerolizumab,MOXR-0916,MOXR0916,RG-7888,RO7021608,CAS:1638935-72-4 |
| Background |
Pogalizumab, also known as MOXR0916 or vonlerolizumab, is a humanized IgG monoclonal antibody that targets OX40 (CD134), a co-stimulatory receptor belonging to the tumor necrosis factor receptor superfamily (TNFRSF). OX40 is predominantly expressed on activated T cells and plays a crucial role in enhancing T-cell proliferation, survival, and cytokine production. By agonistically binding to OX40, pogalizumab aims to potentiate anti-tumor immune responses by promoting effector T-cell activity and inhibiting regulatory T-cell (Treg) functions. |
| Note |
For research use only. Not for use in clinical or therapeutic applications. |
抗体
试剂盒
多肽
探针
蛋白
组织芯片
定制服务咨询